| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Net patient service revenue | 1,101 | 1,068 | 499* | 242 |
| Cost of patient services | 675 | 631 | 214* | 97 |
| Research and development | 2,116 | 1,309 | 153* | 1,429 |
| Selling, general and administrative | 4,745 | 3,813 | 4,556* | 2,808 |
| Depreciation and amortization | 66 | 63 | -8* | 26 |
| Settlement expense (income) | 4 | -6 | 177* | -94 |
| Total operating expenses | 7,606 | 5,810 | 5,092* | 4,266 |
| Loss from operations | -6,505 | -4,742 | -4,593* | -4,024 |
| Interest income | 6 | 5 | 6* | 2 |
| Interest expense | 240 | 233 | 671* | 0 |
| Change in fair value of convertible debt | 0 | 0 | -6,661* | 1,502 |
| Change in fair value of warrant liabilities | 9,784 | -3,538 | -20,167* | 4,963 |
| Loss on issuance of registered direct offering | 0 | 0 | -730* | 0 |
| Loss on consideration shares and warrants | 0 | 0 | -1,277* | 0 |
| Convertible note default penalty | - | - | 0* | 0 |
| Loss on convertible note conversions | 0 | 0 | -2,232* | -772 |
| Income from equity method investments | 3 | 2 | -9* | - |
| Loss on exercise of warrants | - | - | -10,738* | 5,369 |
| Total other expense, net | -10,015 | 3,312 | 11,178* | -1,866 |
| Net gain | -16,520 | -1,430 | 6,585 | -5,890 |
| Change in fair value of convertible note attributed to credit risk | - | - | - | 0 |
| Other comprehensive loss | - | - | - | 0 |
| Comprehensive loss | - | - | - | -5,890 |
| Basic EPS | -0.44 | -0.04 | 0.274 | -0.27 |
| Basic Average Shares | 37,649,382 | 32,325,323 | 24,039,675 | 22,231,178 |
NRX Pharmaceuticals, Inc. (NRXP)
NRX Pharmaceuticals, Inc. (NRXP)